Enzo Spisni

Prof. Enzo Spisni

University of Bologna, Bologna, Emilia-Romagna, Italy
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Molecular Biology of the Cell
Verified
Journal Article
Closed access
Filippo AcconciaFilippo Acconcia
Filippo Acconcia
PAPaolo Ascenzi
Paolo Ascenzi
ABAlessio Bocedi
Alessio Bocedi
Enzo SpisniEnzo Spisni
Enzo Spisni
VTVittorio Tomasi
Vittorio Tomasi
MMMaria Marino
Maria Marino
A fraction of the nuclear estrogen receptor α (ERα) is localized to the plasma membrane region of 17β-estradiol (E2) target cells. We previously reported that ERα is a palmitoylated protein. To gain insight into the molecular mechanism of ERα residence at the plasma membrane, we tested both the role of palmitoylation and the impact of E2 stimulation on ERα membrane localization. The cancer cell lines expressing transfected or endogenous human ERα (HeLa and HepG2, respectively) or the ERα nonpalmitoylable Cys447Ala mutant transfected in HeLa cells were used as experimental models. We found that palmitoylation of ERα enacts ERα association with the plasma membrane, interaction with the membrane protein caveolin-1, and nongenomic activities, including activation of signaling pathways and cell proliferation (i.e., ERK and AKT activation, cyclin D1 promoter activity, DNA synthesis). Moreover, E2 reduces both ERα palmitoylation and its interaction with caveolin-1, in a time- and dose-dependent manner. These data point to the physiological role of ERα palmitoylation in the receptor localization to the cell membrane and in the regulation of the E2-induced cell proliferation.

8 May 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
FRFernando Rizzello
Fernando Rizzello
Enzo SpisniEnzo Spisni
Enzo Spisni
EGElisabetta Giovanardi
Elisabetta Giovanardi
VIVeronica Imbesi
Veronica Imbesi
MSMarco Salice
Marco Salice
PGPaolo Gionchetti
Paolo Gionchetti
Inflammatory bowel diseases (IBD) are currently considered multifactorial pathologies in which various combined environmental factors act on a genetic background, giving rise to a chronic inflammation of the gastrointestinal tract. Among the various environmental factors, it now seems clear that the diet plays the major role in IBD onset and progression. Several clinical studies have attempted to understand the impact of diet in the development and progression of these diseases in order to establish useful guidelines for their management. However, the modest and sometimes contradictory results did not lead to the definition of shared dietary suggestions. On the other hand, food fads and recommendations based on anecdotal episodes are often followed by IBD patients to improve their diet. This review provides a critical overview of existing data on the role of diet as a risk factor for IBD. The methodology used was that of analyzing the results of clinical studies conducted on diet and IBD over the last 12 years through PubMed, as well as analyzing the most relevant studies on nutrients and their possible roles in IBD through the knowledge of the mechanisms by which they can modulate the microbiota or the intestinal physiology.

1 May 2009 in Experimental Cell Research
Verified
Journal Article
Closed access
ASAntonio Strillacci
Antonio Strillacci
CGCristiana Griffoni
Cristiana Griffoni
PSPasquale Sansone
Pasquale Sansone
PPPaola Paterini
Paola Paterini
GPGiulia Piazzi
Giulia Piazzi
VTVittorio Tomasi
Vittorio Tomasi

13 April 2017 in Cancer Research
Verified
Journal Article
Closed access
PDF file
PSPasquale Sansone
Pasquale Sansone
MBMarjan Berishaj
Marjan Berishaj
VRVinagolu K. Rajasekhar
Vinagolu K. Rajasekhar
CCClaudio Ceccarelli
Claudio Ceccarelli
QCQing Chang
Qing Chang
JBJacqueline Bromberg
Jacqueline Bromberg
The hypothesis that microvesicle-mediated miRNA transfer converts noncancer stem cells into cancer stem cells (CSC) leading to therapy resistance remains poorly investigated. Here we provide direct evidence supporting this hypothesis, by demonstrating how microvesicles derived from cancer-associated fibroblasts (CAF) transfer miR-221 to promote hormonal therapy resistance (HTR) in models of luminal breast cancer. We determined that CAF-derived microvesicles horizontally transferred miR-221 to tumor cells and, in combination with hormone therapy, activated an ERlo/Notchhi feed-forward loop responsible for the generation of CD133hi CSCs. Importantly, microvesicles from patients with HTR metastatic disease expressed high levels of miR-221. We further determined that the IL6–pStat3 pathway promoted the biogenesis of onco-miR-221hi CAF microvesicles and established stromal CSC niches in experimental and patient-derived breast cancer models. Coinjection of patient-derived CAFs from bone metastases led to de novo HTR tumors, which was reversed with IL6R blockade. Finally, we generated patient-derived xenograft (PDX) models from patient-derived HTR bone metastases and analyzed tumor cells, stroma, and microvesicles. Murine and human CAFs were enriched in HTR tumors expressing high levels of CD133hi cells. Depletion of murine CAFs from PDX restored sensitivity to HT, with a concurrent reduction of CD133hi CSCs. Conversely, in models of CD133neg, HT-sensitive cancer cells, both murine and human CAFs promoted de novo HT resistance via the generation of CD133hi CSCs that expressed low levels of estrogen receptor alpha. Overall, our results illuminate how microvesicle-mediated horizontal transfer of genetic material from host stromal cells to cancer cells triggers the evolution of therapy-resistant metastases, with potentially broad implications for their control. Cancer Res; 77(8); 1927–41. ©2017 AACR.

1 August 2012 in Food Microbiology
Verified
Journal Article
Closed access
BVBeatrice Vitali
Beatrice Vitali
GMGiovanna Minervini
Giovanna Minervini
CRCarlo Giuseppe Rizzello
Carlo Giuseppe Rizzello
Enzo SpisniEnzo Spisni
Enzo Spisni
SMSimone Maccaferri
Simone Maccaferri
RCRaffaella Di Cagno
Raffaella Di Cagno

25 January 2018 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
BPBarbara Pavan
Barbara Pavan
ADAlessandro Dalpiaz
Alessandro Dalpiaz
LMLuca Marani
Luca Marani
SBSarah Beggiato
Sarah Beggiato
LFLuca Ferraro
Luca Ferraro
Enzo SpisniEnzo Spisni
Enzo Spisni
Geraniol is a natural monoterpene showing anti-inflammatory, antioxidant, neuroprotective and anticancer effects. No pharmacokinetic and bioavailability data on geraniol are currently available. We therefore performed a systematic study to identify the permeation properties of geraniol across intestinal cells, and its pharmacokinetics and bioavailability after intravenous and oral administration to rats. In addition, we systematically investigated the potential hepatotoxic effects of high doses of geraniol on hepatic phase I, phase II and antioxidant enzymatic activities and undertook a hematochemical analysis on mice. Permeation studies performed via HPLC evidenced geraniol permeability coefficients across an in vitro model of the human intestinal wall for apical to basolateral and basolateral to apical transport of 13.10 ± 2.3 × 10-3 and 2.1 ± 0.1⋅× 10-3 cm/min, respectively. After intravenous administration of geraniol to rats (50 mg/kg), its concentration in whole blood (detected via HPLC) decreased following an apparent pseudo-first order kinetics with a half-life of 12.5 ± 1.5 min. The absolute bioavailability values of oral formulations (50 mg/kg) of emulsified geraniol or fiber-adsorbed geraniol were 92 and 16%, respectively. Following emulsified oral administration, geraniol amounts in the cerebrospinal fluid of rats ranged between 0.72 ± 0.08 μg/mL and 2.6 ± 0.2 μg/mL within 60 min. Mice treated with 120 mg/kg of geraniol for 4 weeks showed increased anti-oxidative defenses with no signs of liver toxicity. CYP450 enzyme activities appeared only slightly affected by the high dosage of geraniol.